Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance

Despite the substantial improvement of therapeutic approaches, multiple myeloma (MM) remains mostly incurable. However, immunotherapeutic and especially T cell-based approaches pioneered the therapeutic landscape for relapsed and refractory disease recently. Targeting B-cell maturation antigen (BCMA...

Descripción completa

Detalles Bibliográficos
Autores principales: Füchsl, Franziska, Krackhardt, Angela M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834324/
https://www.ncbi.nlm.nih.gov/pubmed/35159220
http://dx.doi.org/10.3390/cells11030410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834324/
https://www.ncbi.nlm.nih.gov/pubmed/35159220
http://dx.doi.org/10.3390/cells11030410

Ejemplares similares